Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M109274200 on November 7, 2001

J. Biol. Chem., Vol. 277, Issue 5, 3440-3446, February 1, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
277/5/3440    most recent
M109274200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nitz, M.
Right arrow Articles by Bundle, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nitz, M.
Right arrow Articles by Bundle, D. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Unique Solution Structure and Immunochemistry of the Candida albicans beta -1,2-Mannopyranan Cell Wall Antigens*,

Mark NitzDagger , Chang-Chun LingDagger , Albin OtterDagger , Jim E. Cutler§, and David R. BundleDagger ||

From the Dagger  Department of Chemistry, the University of Alberta, Edmonton, Alberta T6G 2G2, Canada and the § Department of Microbiology, Montana State University, Bozeman, Montana 59717-3520

Received for publication, September 25, 2001, and in revised form, November 2, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Synthetic oligomers of the antigenic Candida albicans (1right-arrow2)-beta -mannopyranans adopt a compact solution conformation that leads to numerous inter-residue nuclear Overhauser effects, including unprecedented nuclear Overhauser effects between n and n + 3 residues. In excellent agreement with experimentally determined distances, unrestrained molecular dynamics point to a single family of conformations that approximate a compact helical motif with a three-residue repeat for this unique homopolymer. When the synthetic di- to hexasaccharides were employed as inhibitors of monoclonal antibodies, which protect mice against a lethal dose of the yeast pathogen, a novel pattern of inhibitor activity was observed. Instead of the paradigm first reported by Kabat (Kabat, E. A. (1962) Fed. Proc. 21, 694-701; Kabat, E. A. (1966) J. Immunol. 97, 1-11), wherein homo-oligosaccharides exhibit increasing inhibitory activity with increasing size, here the maximum activity is reached for di- and trisaccharides and diminishes significantly for tetra-, penta-, and hexasaccharides. These immunochemical data correlate with the ordered conformation of the beta -1,2-linked mannopyranan and imply that a uniquely small antigenic determinant has potential as a component of synthetic conjugate vaccines against Candida albicans.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Monoclonal antibodies that protect mice against the pathogenic yeast, Candida albicans (1-3), have been shown to be specific for a cell wall (1right-arrow2)-beta -mannan antigen (4, 5). The unique immunochemical properties of this antigen correlate with its solution conformation and show a sharp contrast with the paradigm first reported by Kabat (6, 7) some 40 years ago that applies to the majority of oligosaccharide-antibody interactions.

C. albicans, the most common etiologic agent in candidiasis (8), commonly affects immunocompromised patients and those undergoing long term antibiotic treatment (9). The number of cases of systemic candidiasis has become a major medical problem in hospitals, where C. albicans is now responsible for up to 25% of nosocomial infections (9). Treatment of these infections is becoming increasingly difficult due to increased drug resistance against known antifungal compounds (10). Humoral and cell-mediated immunity may both play a major role in host defenses against C. albicans. Whereas most patients with serious mucosal infections have defects in their cellular immunity (11), patients with deep tissue invasion seem to lack antibodies against the (1right-arrow2)-beta -mannan oligomer found in the yeast cell wall (12).

Monoclonal antibodies raised against C. albicans cell wall extracts in mice were protective against disseminated candidiasis and vaginal candidiasis (1-3, 13). Further studies on these protective monoclonal antibodies indicated the active antigen to be a (1right-arrow2)-beta -mannan polymer that is present as a component of the cell wall phosphomannan (14) and separately as a phospholipomannan (15). In both forms the (1right-arrow2)-beta -mannan antigen is relatively small consisting of between 2 and 14 residues (16). The immunochemistry and solution properties of this antigen are of great interest because (1right-arrow2)-beta -mannan oligomers have potential as the key epitope of conjugate vaccines (17). Computational studies predicted that homopolysaccharides with this linkage pattern would be of rare occurrence and should exhibit a crumpled conformation to alleviate steric contacts between remote residues (18). To investigate their solution structure and immunochemical properties, a series of short oligomers ranging from di- to hexasaccharides have been synthesized as glycosides and glycoconjugates (Fig. 1) (19, 20). Here the simple glycosides are used to develop a conformational model of the oligosaccharides and to probe the immunochemistry of beta -mannan-specific monoclonal antibodies that protect mice against C. albicans.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   Synthetic di- to hexasaccharide ligands 1-5 and the thio-linked congener 6. Individual ring systems are labeled as shown in Fig. 3.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Oligosaccharides 1-6 (Fig. 1) and their corresponding conjugates with bovine serum albumin were synthesized as reported elsewhere (19, 20). The monoclonal antibodies, mAb B6.1 (IgM) and mAb C3.1 (IgG3), produced as concentrated tissue culture supernatants and diluted ~1:40,000 (B6.1) and ~1:2000 (C3.1) for ELISA1 measurements have been described previously (1-3, 13).

Oligosaccharide Inhibition of Enzyme Immunoassay-- C. albicans mannan (22) obtained by 2-mercaptoethanol extraction of whole cells without subsequent affinity fractionation was dissolved in PBS (10 µg/ml), and the solution was used to coat 96-well ELISA plates (100 µl, 18 h at 4 °C). The plate was washed five times with PBST (PBS containing Tween 20, 0.05% v/v) and blocked for 1 h at room temperature (2% bovine serum albumin/PBS, 100 µl). The monoclonal antibodies were mixed with inhibitor dissolved in PBST at concentrations between 0.1 µM and 1 mM, and the resulting solutions were added to the coated microtiter plate in triplicate and incubated at room temperature for 18 h. The plate was washed with PBST (5 times), and goat anti-mouse (IgG or IgM) antibody conjugated to horseradish peroxidase (diluted 1:2000, Kirkegaard & Perry Laboratories) in PBST (100 µl) was added and incubated for 1 h at room temperature. The plate was washed with PBST (5 times); 3,3',5,5'-tetramethylbenzidine (100 µl, Kirkegaard & Perry Laboratories) was added, and after 2 min the color reaction was stopped by the addition of 1 M phosphoric acid (100 µl). Absorbance was read at 450 nm, and percent inhibition was calculated relative to wells containing antibody without inhibitor.

NMR Methods-- Experiments were carried out on Varian Inova 600- and 800-MHz spectrometers using indirect detection, 5-mm triple resonance, z-gradient probes. Experimental conditions were kept as similar as possible between the two spectrometers, except for inherent field-related differences, and are described here for the 800-MHz data. The sample temperature was 25 °C for compounds 1-3 and 30 °C for compounds 4 and 5. The higher temperature moved the HOD peak upfield from the anomeric signals. For data acquisition and processing VNMR 6.1B software was used. Proton chemical shifts were measured relative to external 0.1% acetone at 2.225 ppm. GCOSY and GTOCSY experiments were record as described earlier (23, 24), the latter with a mixing time of 130 ms at a spin-lock field strength of 6.6 kHz. One scan for each of the 512 t1 incrementations was recorded with a sweep width of 3700 Hz (4.6 ppm), digitized over 4300 data points. Transmitter-based solvent presaturation was used during a 1.5-s relaxation delay, and the acquisition time was 0.6 s. Acquisition parameters for T-ROESY experiments (25) were essentially the same as the ones described for the GTOCSY, except that 24 transients were recorded with a total relaxation time of 2.1 s and a mixing time of 400 ms at a spin-lock field of 4.2 kHz. The first two data points in F2 were back-predicted by linear prediction, and no further base-line corrections were applied (26).

Inter-proton Distances from Cross-peak Volumes-- Correlations of interest were checked carefully for undesired TOCSY contributions and integrated on both sides of the diagonal. To obtain a suitable internal reference, the H1-H5 NOEs of each mannopyranose ring were integrated on each side of the diagonal and averaged, and the resulting value was set to 2.39 Å based on the distance found in relevant crystal structures (27). Unknown inter-proton distances were then calculated based on the usual r-6 NOE-distance relationship. Some overlapping volumes could only be determined based on the known relative intensities of multiplets that were partially overlapped (an example is shown in Fig. 2D).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 2.   800-MHz 1H NMR spectra of pentasaccharide 4. A, one-dimensional spectrum in D2O showing excellent signal dispersion. B, section of the two-dimensional GTOCSY experiment showing connectivities through the entire spin system of ring E, starting from proton H2E. C, section of the T-ROESY experiment showing correlations from the anomeric proton H1E. D, expansion of region C showing n + 2 (E-C) and n + 3 (E-B) as well as some intra-residue NOE contacts.

Molecular Modeling-- Computer models were developed using the Insight II molecular modeling package (version 2.9.5 from Molecular Simulations Inc.) running on a Silicon Graphics Indigo II computer. All energy calculations were carried out in vacuo with a dielectric constant of 80.0 using the AMBER-plus force field with exo-anomeric potentials (28). To locate a consensus minimum energy conformation, an unrestrained simulated annealing protocol was used (29). In brief, a high temperature-simulated annealing run generated 10 random energy structures. The ring geometries were enforced by scaling the ring torsional energy terms by 7. These structures were then separately cooled in 50 K steps, and at each step a 1-ps molecular dynamics was performed from 500 to 300 K and then to 10 K in 10 K per 1-ps steps and finally to 5 K. Each annealed structure was then minimized using a steepest descent algorithm. The lowest energy structure was used for a 5-ns molecular dynamics run at 300 K. Theoretical time-averaged 1H-1H (<r-6>) distances were then calculated using MDPROCESS software.2

Tri- to pentasaccharides 2-4 and the thio-linked tetrasaccharide 6 were modeled as outlined above. Details for modeling the pentasaccharide 4 are provided below, whereas further details related to the other structures 1-3 and 6 are available in the Supplemental Material.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

NMR Chemical Shifts-- Unambiguous 1H and 13C chemical shifts for oligosaccharides 1-6 were established by a combination of GCOSY, GTOCSY, and HMQC experiments. The most remarkable observation considering the homo-polymeric nature of oligosaccharides 1-5 was the discrete signal dispersion in their 1H NMR spectra (Fig. 2A). The excellent dispersion of 1H signals permits the spin system of each hexose residue of the homo-oligomers to be assigned (Fig. 2, A and B). Although the resonances of protons H-1 to H-4 for each pyranose ring showed excellent dispersion (Table I), the H-5 and H-6 resonances exhibited severe overlap (not shown).

                              
View this table:
[in this window]
[in a new window]
 
Table I
1H NMR chemical shifts (in ppm) for oligosaccharide glycosides 2-6.

A comparison of the NMR data of the synthetic structures with data for oligomers (30, 31) isolated from the yeast cell wall by acid hydrolysis shows similar 1H and 13C chemical shifts (Supplemental Material Tables I and II). Hemiacetals present in the isolated oligomers cause chemical shift differences and considerable spectral complexity, because both alpha  and beta  forms of the terminal residue exist and propagate chemical shift changes well beyond the terminal reducing hexose residue (30, 31). Synthetic oligomers by comparison are free of this complicating factor, because the terminal mannose residue is protected as a beta -propyl glycoside.

NOE correlations between protons on either side of each glycosidic linkage established the residue identity of the spin systems of adjacent pyranose rings and confirmed their sequence within each linear oligomer. NOEs were measured from T-ROESY spectra of the oligomers (1-5) and revealed numerous contacts between non-contiguous residues, as illustrated for pentasaccharide 4 (Fig. 3). The presence of contacts between n + 2 and n + 3 residues is clearly evident in Fig. 2D. All of the anticipated strong NOEs due to inter-glycosidic contacts between H-1 and H-2 of adjacent residues were present and easily quantified due to the signal dispersion of the H-1 and H-2 protons.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 3.   NOE contacts between non-contiguous residues of pentasaccharide 4. Mannopyranose rings are labeled alphabetically starting at the reducing terminus.

The T-ROESY cross-peak volumes were quantified for the tri-, tetra-, and pentasaccharide (2-4) and for the thio-linked tetrasaccharide 6. These data were used to derive conformationally averaged inter-proton distances (Table II). Hexasaccharide 5 exhibited spectral overlap of several important resonances, and the ROE contacts from this structure were not quantified. Similar distances observed across the glycosidic linkages of the oligomers 1-4 and 6 are indicative of compact, repetitive solution structures. The distances also suggest the inferred structure is not just a result of steric interactions between distant, non-contiguous residues but represent a population of low energy conformations with similar torsional angles about the glycosidic linkages. If steric interactions between non-contiguous residues were limiting the conformations of the oligomers, the shorter oligomers would be expected to have distances that differ from those of the higher molecular weight counterparts.

                              
View this table:
[in this window]
[in a new window]
 
Table II
NOE contacts for (1right-arrow2)-beta -mannopyranosyl tri-, tetra-, pentasaccharides 2-4, and thio-linked tetrasaccharide 6

Molecular Modeling-- Unrestrained molecular dynamics were carried out for oligomers 2-4 and for the thio-analogue 6, and the resulting model for the pentasaccharide 4 is discussed below (data for the other oligomers are available in the Supplemental Material, Table III and Figs. 1-4).

                              
View this table:
[in this window]
[in a new window]
 
Table III
Comparison of theoretical and experimental inter-proton distances for pentasaccharide 4

Comparison of the 10 structures of the pentasaccharide obtained from the simulated annealing protocol showed a single family of low energy conformations (Fig. 4A). A static model of the pentasaccharide in one of these conformations shows the helical nature of this polysaccharide (Fig. 4B). The three-dimensional repeating unit approximates three mannose residues. This is illustrated by a CPK model of a tricolor repeat that displays the residue repeating nature of the helix type structure (Fig. 4C).


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 4.   Structure of annealed pentasaccharide 4. A, structures of the low energy family generated from the simulated annealing run. B, tube model (stereo) of the lowest energy structure from A. C, CPK surface (stereo) of the lowest energy structure (shown in B) with green-red-blue-green-red coloring of sequential hexose residues to indicate the near 3-residue helical repeat.

Theoretical inter-proton distances were calculated from the 5-ns molecular dynamics run performed at 300 K. The data compared well with distances determined from experimental NOEs (Table III) (29). During the dynamics run, the oligosaccharide stayed within the range of glycosidic torsional angles represented by the family of conformations generated by simulated annealing.

A comparison of the conformations and molecular dynamics of the tri-, tetra-, and pentasaccharides shows similar low energy conformations for each of the oligosaccharides 2-4. The thio-linked oligosaccharide 6 showed two minimum energy structures about the terminal thioglycosidic linkage. Two conformations are explored at phi  angles centered about the two gauche conformations 60° and -60°. The first of these would be favored by the exo-anomeric effect, but the force field was not parameterized for the magnitude of this effect in the case of sulfur. Although expected based on the findings of others (32-37) which show thioglycosides to be more flexible than their O-linked counterparts, the anti-conformer was not sampled during the MD calculations of the thio-linkage (Phi ,Psi trajectory maps generated from the molecular dynamics for each glycosidic linkage are available in the Supplemental Material, Fig. 4).

Antibody Binding to Synthetic Glycans-- The affinity of IgM and IgG monoclonal antibodies, generated by immunization of mice with liposomal extracts of the C. albicans cell wall, for the synthesized propyl glycosides 1-6 was determined by competitive ELISA (Table IV).

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Inhibition by synthetic oligosaccharides 1-6 of the binding of monoclonal antibodies B6.1 (IgM) and C3.1 (IgG) to C. albicans mannan antigen

The IgM antibody, B6.1, showed a surprisingly high affinity for the di- and trisaccharides when compared with tetrasaccharide 3, pentasaccharide 4, and hexasaccharide 5 (Table 4 and Fig. 5). The inhibitory power of the propyl 1-thio-beta -D-mannopyranosyl-beta -D-mannopyranotrioside 6 fell between that of the tri- and tetrasaccharide (Table IV).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 5.   ELISA inhibition data for monoclonal antibodies B6.1 (A) and C3.1 (B). Inhibition by synthetic oligosaccharides 1-5 of monoclonal antibody binding to C. albicans extract. black-square, propyl (1right-arrow2)-beta -D-mannopyranobioside (1); black-triangle, propyl (1right-arrow2)-beta -D-mannopyraontrioside (2); black-down-triangle , propyl (1-thio-beta -D-mannopyranosyl)-(1right-arrow2)-beta -D-mannopyranotrioside (6); black-diamond , propyl (1right-arrow2)-beta -D-mannopyranotetroside (3); , propyl (1right-arrow2)-beta -D-mannopyranopentoside (4); , propyl (1right-arrow2)-beta -D-mannopyranohexoside (5).

The same panel of oligomannosides 1-6 with IgG (C3.1) antibody showed a trend in affinities similar to those observed with mAb B6.1. Again di- and trisaccharides had the highest affinities but were 5- and 2-fold higher than for B6.1 (Table IV). The other (1right-arrow2)-beta -oligomannosides had similar affinities (Fig. 5).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The chemical synthesis (19, 20) of oligomers of the (1right-arrow2)-beta -mannan has provided a series of compounds locked in the anomeric configuration of the native antigen, thereby facilitating a thorough analysis of the solution structure and immunochemical properties of this important C. albicans antigen.

The excellent signal dispersion observed for the proton resonances of the (1right-arrow2)-beta -mannopyranan oligomers 1-5 suggests they are conformationally distinct, in contrast to other homo-oligomers such as (1right-arrow2)-alpha -mannopyranotetrose (38) or maltoheptose ((1right-arrow4)-alpha -glucopyranoheptose) (39), where the conformationally sensitive H-1 resonances have similar chemical shifts. Most homopolysaccharides exhibit this degeneracy in chemical shift (40, 41), because internal residues sample virtually identical chemical environments. The distinct 1H chemical shifts observed for the H-1 and H-2 resonances of each mannose residue of tetrasaccharide 3 suggest that oligomeric (1right-arrow2)-beta -mannopyranans are conformationally distinct in contrast to many homo-oligomers. Similar exceptions occur for both the alpha - and beta -1,2-linked oligomers of glucose (42, 43). These two examples and the (1right-arrow2)-beta -mannopyranan were identified by modeling studies as belonging to a class of homopolymers that would be expected to form relatively stiff and crumpled conformations (18). Chemical shift characteristics of oligomers isolated from C. albicans cell walls have been noted and tentatively interpreted in terms of a collapsed conformation (44).

The use of NOEs to define solution conformations of oligosaccharides is most effective when there are numerous NOEs between hexose residues. This occurs for well defined oligosaccharide conformations that most often result from branching through vicinal substitution, as is the case with the blood group A and B antigens. In this and other such structures (45-47), NOE contacts between non-contiguous residues (for example n and n + 2) often occur spanning the branched pyranose ring. A linear homopolysaccharide can achieve the equivalent of vicinal substitution only if the hydroxyl group adjacent to the anomeric center is the site for chain extension. For aldohexoses this occurs for 1,2-linkages. However, many 1,2-linked homo-oligomers such as those of the Brucella abortus A antigen yield few if any NOE contacts between non-contiguous residues (48). The observation of multiple NOE contacts between non-contiguous residues in the (1right-arrow2)-beta -mannopyranans studied here is exceptional in oligosaccharide conformational analysis. The presence of NOE interactions between residues residues A and D (n to n + 3 contacts) is to our knowledge unprecedented and indicative of a compact structure.

Unrestrained molecular dynamics of the mannopyranans generated a discrete model of these unique oligosaccharides, which agreed well with the NOE measurements. A comparison of the conformational space sampled by the oligosaccharides indicates that the tri-, tetra-, and pentasaccharides explore very similar torsional angles across all their linkages. The family of conformations sampled is consistent with a model that imparts helical character to this glycan chain (Fig. 4). The repeating unit is approximately 3 residues long, but due to the inherent flexibility about glycosidic torsional angles, the overlap of residues n and n + 3 is only approximate (Supplemental Material Fig. 5). In this family of conformations, hydroxyls are oriented into solution, and a hydrophobic core is made up of the alpha -faces of the mannose rings. It is of interest to note that after this work was completed a different chemical synthesis of the (1right-arrow2)-beta -mannopyranan oligosaccharides was reported, together with a crystal structure of a tetrasaccharide with attached organic protecting groups (49). The gross features of this molecule appear to be very closely related to the aqueous solution structure proposed here.

It is of interest to consider possible implications of this oligosaccharide structure. The helix hides the glycosidic linkages at its core possibly limiting the accessibility to endomannosidases. The hydrophobic faces of the rings are also shielded, except for the terminal residues, which likely have implications for the binding of oligomers by antibodies or lectins, where hydrophobic surfaces can be important.

The distinctive conformation of the beta -1,2-linked pyranomannans correlates with the unique immunochemistry of these oligomers. Di- and trisaccharides 1 and 2 exhibit significantly higher affinity for the monoclonal antibodies than larger tetra- to hexasaccharides (3-5). In fact the tetrasaccharide 3 and hexsaccharide 5 are 10 and 100 times poorer inhibitors of IgG (monoclonal antibody C3.1) binding to the cell wall mannan than disaccharide 1. Similar trends are observed for the IgM antibody (B6.1), although here trisaccharide 2 is a marginally better inhibitor than disaccharide 1. This size specificity can be contrasted with the findings of Kabat (6, 7), who showed for human polyvalent sera raised against the homopolymeric dextran antigen that the inhibitory power of oligosaccharides steadily increased as the size of an inhibitor increased and reached a plateau at about the size of a hexamer.

Of the two general types of antibody-binding site, groove and cavity, predicted for carbohydrate epitopes, the groove-type might be expected to show epitope activity that steadily increases with ligand size. Indeed, when the small energetic gains that can arise from pyranose residues that flank the antigenic determinant are considered, the optimal size of the inhibitor, found by Kabat (6, 7), correlates well with the size of oligosaccharides that fill the binding sites of groove-type antibodies studied by crystallography (50-55). Exceptions to this generality are seen for certain homo- and heteropolysaccharides containing sialic acid where a unique bioactive conformation dictates a more pronounced dependence on oligomer length (56-58). The C. albicans antibodies do not conform to the characteristics of the second type of binding site. Cavity sites typically recognize the terminal sugars of a polymeric chain in a manner similar to that described for the crystal structure of the Vibrio cholerae carbohydrate epitope complexed with a monoclonal antibody (55). In this complex the terminal residue of the polysaccharide antigen contributes 90% of the binding energy, and inhibitors to this type of chain end specific antibody are expected to show inhibition data that are virtually unchanged on a molar basis as ligand molecular weight increases (59). However, there is no precedence for sharply decreasing inhibitory power with increasing oligosaccharide size.

The immune response to (1right-arrow2)-beta -mannopyranans is unique in two ways. (i) The larger tetra- to hexasaccharides do not possess the same epitope as smaller oligomers and therefore have weaker affinity for the antibodies. (ii) In the case of the protective antibodies, the immune system has selected for antibodies against short oligomers.

The first point is borne out for structures determined by NMR and molecular modeling. Due to the helical nature of the oligomers, antibodies raised against the short oligomers (2-3 residues) may experience steric conflicts when binding larger oligomers, because the fourth residue is in close proximity to the first residue. There is precedence for steric effects, because residues flanking an antibody-binding site can be forced to adopt higher energy conformations to relieve steric interactions with the surface of the antibody (60). The presence of a steric interaction with the fourth residue of the oligomer is consistent with the higher activity of the thio-linked tetrasaccharide 6 over its O-linked analogue 3, an atypical observation for thioglycoside mimetics, which usually bind their protein receptors with lower affinity (35). Due to the increased flexibility of the thioglycosidic bond (Supplemental Material), the terminal residue is better able to relieve its steric interaction with the antibody-binding site by adopting other low energy conformations that place the terminal mannopyranose ring away from the antibody surface.

Second, protective monoclonal antibodies recognize short oligosaccharide sequences or the terminal hexose residues of larger oligomers. It is surprising that both protective antibodies of different immunoglobulin subclasses show similar affinities for the synthetic oligomers and therefore recognize the natural oligomers in a similar fashion. Given the conformation of the oligosaccharides, it may be difficult for an antibody to recognize internal residues of the oligomer, and in this sense the conformation of the antigen dictates the immune response to it. If the internal residues were recognized, such antibodies could be forced to bind non-contiguous residues, which would be entropically disfavored due to the higher degrees of freedom between non-contiguous residues (this can be most readily appreciated by examining a model of an undecasaccharide, Supplemental Material Fig. 5).

Expression of significant amounts of low molecular weight antigen may account for the induction of protective antibodies C3.1 and B6.1. In fact, analysis of the relative abundance of (1right-arrow2)-beta -mannopyranans by fluorophore-assisted carbohydrate electrophoresis points to a high incidence of di- and trisaccharide epitopes in the acid-sensitive portion of the mannan (61).

These findings have direct implications for the design of anti-C. albicans conjugate vaccines. It has been suggested that intermediate sized oligosaccharides (15-20 hexose residues in length) are required for the carbohydrate component of conjugate vaccines designed to prevent bacterial diseases (62, 63). The underlying assumption was that protein-conjugated oligosaccharide should be of sufficient size to assume a conformation similar to its native state on the bacterial cell surface. Commercial carbohydrate-based conjugate vaccines are for the most part developed from isolated polysaccharides rather than defined synthetic oligomers (64). Only recently have chemical methods reached the sophistication to tackle the synthesis of such large oligosaccharide targets (65). In the case of (1right-arrow2)-beta -mannopyranans of the yeast cell wall, it appears that the size of the epitope that induces protective antibody falls within the range of 2-3 hexose residues, which is significantly smaller than the 15-20 sugar residues required to create a practical immunogen that can induce polysaccharide-specific antibodies effective against pathogenic organisms (62, 64). In the case of the 2,8-linked sialic acid capsule of Neisseria meningitidis and related polysaccharides with sialic acid-containing epitopes, the size requirement can be even larger than 15-20 sugar residues, because the immunizing epitope must be part of a shallow helical determinant present in the native antigen (21, 56, 57, 66, 67).

On the basis of its helical conformational and immunochemical properties, and in sharp contrast to the preceding examples, we suggest that a small di- or trisaccharide or suitable analogues of the type described here coupled to protein will provide an antigen sufficient for protection against C. albicans.

    ACKNOWLEDGEMENTS

We thank Joanna Sadowska for technical support. NMR spectra at 800 MHz were obtained at the Canadian National High Field NMR Center funded by the Canadian Institutes of Health Research, National Science and Engineering Research Council of Canada, Alberta Heritage Foundation for Medical Research, and the University of Alberta.

    FOOTNOTES

* This work was supported in part by research grants from the National Science and Engineering Research Council of Canada (to D. R. B.), the University of Alberta, and National Science and Engineering Research Council of Canada postgraduate studentship awards (to M. N.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at http://www.jbc.org) contains Tables I-III and Figs. 1-5.

Supported by National Institutes of Health Research Grants RO1 AI24912, RO1 DE13982, and PO1 AI37194.

|| To whom correspondence should be addressed: Dept. of Chemistry, the University of Alberta, Edmonton, Alberta T6G 2G2, Canada. Tel.: 780-492-8808; Fax: 780-492-7705; E-mail: Dave.Bundle@ualberta.ca.

Published, JBC Papers in Press, November 7, 2001, DOI 10.1074/jbc.M109274200

2 T. J. Rutherford, unpublished software.

    ABBREVIATIONS

The abbreviations used are: ELISA, enzyme-linked immunosorbent assay; PBS, phosphate-buffered saline; NOE, nuclear Overhauser effect; mAb, monoclonal antibody.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Han, Y., and Cutler, J. E. (1995) Infect. Immun. 63, 2714-2719[Abstract]
2. Han, Y., and Cutler, J. E. (1997) J. Infect. Dis. 175, 1169-1175[Medline] [Order article via Infotrieve]
3. Han, Y., Riesselman, M. H., and Cutler, J. E. (2000) Infect. Immun. 68, 1649-1654[Abstract/Free Full Text]
4. Shibata, N., Kobayashi, H., Tojo, M., and Suzuki, S. (1986) Arch. Biochem. Biophys. 251, 697-708[CrossRef][Medline] [Order article via Infotrieve]
5. Shibata, N., Fukasawa, S., Kobayashi, H., Tojo, M, Yonezu, T., Ambo, A., Ohkubo, Y., and Suzuki, S. (1989) Carbohydr. Res. 187, 239-253[CrossRef][Medline] [Order article via Infotrieve]
6. Kabat, E. A. (1962) Fed. Proc. 21, 694-701
7. Kabat, E. A. (1966) J. Immunol. 97, 1-11[Abstract/Free Full Text]
8. Casadevall, A., Cassone, A., Bistoni, F., Cutler, J. E., Magliani, W., Murphy, J. W., Polonelli, L., and Romani, L. (1998) Med. Mycol. 36 Suppl. 1, 95-105
9. Beck-Sagué, C. M., and Jarvis, W. R. (1993) J. Infect. Dis. 167, 1247-1251[Medline] [Order article via Infotrieve]
10. Odds, F. C. (1996) Int. J. Antimicrob. Agents 6, 145-147
11. Levitz, S. M. (1992) Clin. Infect. Dis. 14, 37-42
12. Jouault, T., Delaunoy, C., Sendid, B., Ajana, F., and Poulain, D. (1997) Clin. Diagn. Lab. Immunol. 4, 328-333[Abstract]
13. Han, Y., Kozel, T. R., Zhang, M. X., MacGill, R. S., Carroll, M. C., and Cutler, J. E. (2001) J. Immunol. 167, 1550-1557[Abstract/Free Full Text]
14. Han, Y., Kanbe, T., Cherniak, R., and Cutler, J. E. (1997) Infect. Immun. 65, 4100-4107[Abstract]
15. Trinel, P.-A., Plancke, Y., Gerold, P., Jouault, T., Delplace, F., Shwarz, R. T., Strecker, G., and Poulain, D. (1999) J. Biol. Chem. 274, 30520-30526[Abstract/Free Full Text]
16. Trinel, P. A., Lepage, G., Joulault, T., Strecker, G., and Poulain, D. (1997) FEBS Lett. 416, 203-206[CrossRef][Medline] [Order article via Infotrieve]
17. Han, Y., Melinda, A., and Cutler, J. E. (1999) J. Infect. Dis. 179, 1477-1484[CrossRef][Medline] [Order article via Infotrieve]
18. Rees, D. A., and Scott, W. E. (1971) J. Chem. Soc. 469-479
19. Nitz, M., and Bundle, D. R. (2001) J. Org. Chem. 66, 8411-8423[CrossRef][Medline] [Order article via Infotrieve]
20. Nitz, M., and Bundle, D. R. (2000) Org. Lett. 2, 2939-2942[CrossRef][Medline] [Order article via Infotrieve]
21. Brisson, J.-R., Baumann, H., Imberty, A., Perez, S., and Jennings, H. J. (1992) Biochemistry 31, 4996-5004[CrossRef][Medline] [Order article via Infotrieve]
22. Kanbe, T., Han, Y., Redgrave, B., Riesselman, M. H., and Cutler, J. E. (1993) Infect. Immun. 61, 2578-2584[Abstract/Free Full Text]
23. Hurd, R. E. (1990) J. Magn. Reson. 87, 422-428
24. Otter, A., Hindsgaul, O., and Bundle, D. R. (1995) Carbohydr. Res. 275, 381-389[CrossRef][Medline] [Order article via Infotrieve]
25. Hwang, T.-L., and Shanka, A. J. (1992) J. Am. Chem. Soc. 114, 3157-3159[CrossRef]
26. Babcook, D. M., Sahasrabudhe, P. V., and Gmeiner, W. H. (1996) Magn. Reson. Chem. 34, 851-857[CrossRef]
27. Jeffrey, G. A., McMullan, R. K., and Takagi, S. (1977) Acta Crystallogr. Sect. B Struct. Sci. 33, 728-737[CrossRef]
28. Homans, S. W. (1990) Biochemistry 29, 9110-9118[CrossRef][Medline] [Order article via Infotrieve]
29. Rutherford, T. J., Spackman, D. G., Simpson, P. J., and Homans, S. W. (1994) Glycobiology 4, 59-68[Abstract/Free Full Text]
30. Shibata, N., Hisamichi, K., Kobayashi, H., and Suzuki, S. (1993) Arch. Biochem. Biophys. 302, 113-117[CrossRef][Medline] [Order article via Infotrieve]
31. Faille, C., Wieruszeski, J.-M., Michalski, J.-C., Poulain, D., and Strecker, G. (1992) Carbohydr. Res. 236, 17-27[CrossRef][Medline] [Order article via Infotrieve]
32. Montero, E., Garcia-Herrero A., Asenso, J. L., Hirai, K., Ogawa, S., Santoyo-González, Canada, J. F., and Jiménez-Barbero, J. (2000) Eur. J. Org. Chem. 1945-1952
33. Anuilera, B., Jiménez-Barbero, J., and Fernández-Mayoralas, A. (1998) Carbohydr. Res. 308, 19-27[CrossRef][Medline] [Order article via Infotrieve]
34. Montero, E., Vallmitjana, M., Pérez-Pons, J. A., Querol, E., Jiménez-Barbero, J., and Canada, F. J. (1998) FEBS Lett. 421, 243-248[CrossRef][Medline] [Order article via Infotrieve]
35. Nilsson, U., Johansson, R., and Magnusson, G. (1996) Chem. Eur. J. 2, 295-302
36. Geyer, A., Hummel, G., Eisele, T., Reinhardt, S., and Schmidt, R. R. (1996) Chem. Eur. J. 2, 981-988
37. Bock, K., Duus, J. Ø., and Refn, S. (1994) Carbohydr. Res. 253, 51-61[CrossRef][Medline] [Order article via Infotrieve]
38. Ogawa, T., and Yamamoto, H. (1982) Carbohydr. Res. 104, 271-283[CrossRef]
39. Sugiyama, H., Toyohiko, N., Horii, M., Motohashi, K., Sakai, J., Usui, T., Hisamichi, K., and Ishiyama, J. (2000) Carbohydr. Res. 325, 177-182[CrossRef][Medline] [Order article via Infotrieve]
40. Caroff, M., Bundle, D. R., Perry, M. B., Cherwonogrodzky, J. W., and Duncan, J. R. (1984) Infect. Immun. 46, 384-388[Abstract/Free Full Text]
41. Kihlberg, J., and Bundle, D. R. (1991) Carbohydr. Res. 216, 67-78[CrossRef][Medline] [Order article via Infotrieve]
42. Ogawa, T., and Takanashi, Y. (1983) Carbohydr. Res. 123, C16-C18[CrossRef]
43. Pozsgay, V., and Robbins, J. B. (1995) Carbohydr. Res. 277, 51-66[CrossRef][Medline] [Order article via Infotrieve]
44. Shibata, N., Hisamichi, K., Kikuchi, T., Kobayashi, H., Okawa, Y., and Suzuki, S. (1992) Biochemistry 31, 5680-5686[CrossRef][Medline] [Order article via Infotrieve]
45. Otter, A., Lemieux, R. U., Ball, R. G., Venot, A. P., Hindsgaul, O., and Bundle, D. R. (1999) Eur. J. Biochem. 259, 295-303[Medline] [Order article via Infotrieve]
46. Lemieux, R. U., Bock, K., Delbaere, L. T. J., Koto, S., and Rao, V. S. (1980) Can. J. Chem. 58, 631-653[CrossRef]
47. Bock, K., Meldal, M., Bundle, D. R., Iversen, T., Pinto, B. M., Garegg, P. J., Kvanström, I., Norberg, T., Lindberg, A. A., and Svenson, S. B. (1984) Carbohydr. Res. 130, 35-53[CrossRef][Medline] [Order article via Infotrieve]
48. Peters, T., Brisson, J.-R., and Bundle, D. R. (1990) Can. J. Chem. 68, 979-988[CrossRef]
49. Crich, D., Li., H., Yao, Q., Wink, D. J., Sommer, R. D., and Rheingold, A. L. (2001) J. Am Chem. Soc. 123, 5826-5828[CrossRef][Medline] [Order article via Infotrieve]
50. Cygler, M., Rose, D. R., and Bundle, D. R. (1991) Science 253, 442-446[Abstract/Free Full Text]
51. Rose, D. R., Przybylska, M., To, R. J., Kayden, C. S., Oomen, R. P., Vorberg, E., Young, N. M., and Bundle, D. R. (1993) Protein Sci. 2, 1106-1113[Medline] [Order article via Infotrieve]
52. Vyas, M. N., Vyas, N. K., Meikle, P. J., Sinnott, B., Pinto, B. M., Bundle, D. R., and Quiocho, F. A. (1993) J. Mol. Biol. 231, 133-136[CrossRef][Medline] [Order article via Infotrieve]
53. Bundle, D. R. (1998) in Carbohydrates (Hecht, S., ed) , pp. 370-440, Oxford University Press Inc., Oxford
54. Jeffrey, P. D., Bajorath, J., Chang, C. Y., Yelton, D., Hellstrom, I., Hellstrom, K. E., and Sheriff, S. (1995) Nat. Struct. Biol. 2, 466-471[CrossRef][Medline] [Order article via Infotrieve]
55. Villeneuve, S., Souchon, H., Riottot, M.-M., Mazié, J.-C., Lei, P.-S., Glaudemans, C. P. J., Ková, P., Fournier, J.-M., and Alzari, P. M. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 8433-8438[Abstract/Free Full Text]
56. Wessels, M. R., Muñoz, A., and Kasper, D. L. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 9170-9174[Abstract/Free Full Text]
57. Michon, F., Brisson, J.-R., and Jennings, H. J. (1987) Biochemistry 26, 8399-8405[CrossRef][Medline] [Order article via Infotrieve]
58. Evans, S. V., Sigurskjold, B. W., Jennings, H. J., Brisson, J.-R., To, R., Altman, E., Frosch, M., Weisgerber, C., Kratzin, H., Klebert, S., Vaesen, M., Bitter-Suermann, D., Rose, D. R., Young, N. M., and Bundle, D. R. (1995) Biochemistry 34, 6737-6744[CrossRef][Medline] [Order article via Infotrieve]
59. Glaudemans, C. P. J. (1991) Chem. Rev. 91, 25-33[CrossRef]
60. Milton, M. J., and Bundle, D. R. (1998) J. Am. Chem. Soc. 120, 10547-10548[CrossRef]
61. Goins, T. L., and Cutler, J. E. (2000) Infect. Immun. 38, 2862-2869
62. Mäkelä, O., Peterfy, F., Outschoorn, I. G., Richter, A. W., and Seppälä, I. (1984) Scand. J. Immunol. 19, 541-550[CrossRef][Medline] [Order article via Infotrieve]
63. Mäkelä, O., Seppälä, I., and Pelkonen, J. (1985) Eur. J. Biochem. 15, 827-833
64. Pozsgay, V. (1980) Adv. Carbohydr. Chem. Biochem. 56, 153-199
65. Pozsgay, V., Chu, C., Pannell, L., Wolfe, J., Robbins, J. B., and Schneerson, R. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 5194-5197[Abstract/Free Full Text]
66. Brisson, J.-R., Uhrinova, S., Woods, R. J., van der Zwan, M., Jarrell, H. C., Paoletti, L. C., Kasper, D. L., and Jennings, H. J. (1997) Biochemistry 36, 3278-3292[CrossRef][Medline] [Order article via Infotrieve]
67. Zou, W., Mackenzie, R., Therien, L., Hirama, T., Yang, Q., Gidney, M. A., and Jennings, H. J. (1999) J. Immunol. 163, 820-825[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J BiochemHome page
E. Maes, C. Mille, X. Trivelli, G. Janbon, D. Poulain, and Y. Guerardel
Molecular Phenotyping of Mannosyltransferases-Deficient Candida albicans Cells by High-Resolution Magic Angle Spinning NMR
J. Biochem., April 1, 2009; 145(4): 413 - 419.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Xin, S. Dziadek, D. R. Bundle, and J. E. Cutler
Synthetic glycopeptide vaccines combining {beta}-mannan and peptide epitopes induce protection against candidiasis
PNAS, September 9, 2008; 105(36): 13526 - 13531.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Mille, P. Bobrowicz, P.-A. Trinel, H. Li, E. Maes, Y. Guerardel, C. Fradin, M. Martinez-Esparza, R. C. Davidson, G. Janbon, et al.
Identification of a New Family of Genes Involved in {beta}-1,2-Mannosylation of Glycans in Pichia pastoris and Candida albicans
J. Biol. Chem., April 11, 2008; 283(15): 9724 - 9736.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
H. Xin and J. E. Cutler
Hybridoma Passage In Vitro May Result in Reduced Ability of Antimannan Antibody To Protect against Disseminated Candidiasis
Infect. Immun., July 1, 2006; 74(7): 4310 - 4321.
[Abstract] [Full Text] [PDF]


Home page
MicrobiologyHome page
B. L. Granger, M. L. Flenniken, D. A. Davis, A. P. Mitchell, and J. E. Cutler
Yeast wall protein 1 of Candida albicans
Microbiology, May 1, 2005; 151(5): 1631 - 1644.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Mille, G. Janbon, F. Delplace, S. Ibata-Ombetta, C. Gaillardin, G. Strecker, T. Jouault, P.-A. Trinel, and D. Poulain
Inactivation of CaMIT1 Inhibits Candida albicans Phospholipomannan {beta}-Mannosylation, Reduces Virulence, and Alters Cell Wall Protein {beta}-Mannosylation
J. Biol. Chem., November 12, 2004; 279(46): 47952 - 47960.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. P. Hobson, C. A. Munro, S. Bates, D. M. MacCallum, J. E. Cutler, S. E. M. Heinsbroek, G. D. Brown, F. C. Odds, and N. A.R. Gow
Loss of Cell Wall Mannosylphosphate in Candida albicans Does Not Influence Macrophage Recognition
J. Biol. Chem., September 17, 2004; 279(38): 39628 - 39635.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. E. Ralton, T. Naderer, H. L. Piraino, T. A. Bashtannyk, J. M. Callaghan, and M. J. McConville
Evidence That Intracellular {beta}1-2 Mannan Is a Virulence Factor in Leishmania Parasites
J. Biol. Chem., October 17, 2003; 278(42): 40757 - 40763.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
277/5/3440    most recent
M109274200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nitz, M.
Right arrow Articles by Bundle, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nitz, M.
Right arrow Articles by Bundle, D. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement